title: Nitric oxide donors and selective carbonic anhydrase inhibitors: a dual pharmacological approach for the treatment of glaucoma, cancer and osteoporosis.
abstract: Due to the recognized biological role of nitric oxide (NO) donating derivatives and of selective inhibitors of specific human carbonic anhydrase isoforms (CA, EC 4.2.1.1), promising compounds having an aromatic/heterocyclic primary sulfonamide and functionalized with NO-releasing moieties have been designed. These bifunctional agents have been tested in vitro and in vivo to assess their dual pharmacological activity. According to the encouraging results they could be proposed for the treatment of angle-open glaucoma, cancer regression and osteoporosis, in which both NO and CA activities are involved.
authors.affiliation: Department of Pharmacy, "G. D'Annunzio" University of Chieti-Pescara, Via dei Vestini 31, 66100 Chieti, Italy. simone.carradori@unich.it.
authors.forename: Simone
authors.initials: S
authors.lastname: Carradori
authors.affiliation: Department of Pharmacy, "G. D'Annunzio" University of Chieti-Pescara, Via dei Vestini 31, 66100 Chieti, Italy. a.mollica@unich.it.
authors.forename: Adriano
authors.initials: A
authors.lastname: Mollica
authors.affiliation: Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy. celeste.demonte@uniroma1.it.
authors.forename: Celeste
authors.initials: C
authors.lastname: De Monte
authors.affiliation: Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy. arianna.granese@uniroma1.it.
authors.forename: Arianna
authors.initials: A
authors.lastname: Ganese
authors.affiliation: Laboratorio di Chimica Bioinorganica, Università degli Studi di Firenze, Via della Lastruccia 3, 50019 Sesto Fiorentino (Firenze), Italy. claudiu.supuran@unifi.it.
authors.forename: Claudiu T
authors.initials: CT
authors.lastname: Supuran
mesh_terms: D002257:Carbonic Anhydrase Inhibitors / Q000008:administration & dosage*; D002256:Carbonic Anhydrases / Q000235:genetics / Q000378:metabolism; D005901:Glaucoma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009569:Nitric Oxide / Q000378:metabolism; D010024:Osteoporosis / Q000188:drug therapy* / Q000473:pathology
chemical_list: D002257:Carbonic Anhydrase Inhibitors; D009569:Nitric Oxide; D002256:Carbonic Anhydrases
references.citation: Chem Soc Rev. 2012 May 21;41(10):3742-52
references.pmid: 22362384
references.citation: Ann N Y Acad Sci. 2002 May;962:360-71
references.pmid: 12076987
references.citation: J Enzyme Inhib Med Chem. 2013 Apr;28(2):294-8
references.pmid: 22380772
references.citation: Biochem Biophys Res Commun. 2013 Feb 22;431(4):647-51
references.pmid: 23337501
references.citation: Invest Ophthalmol Vis Sci. 2014 Aug 14;55(8):5005-15
references.pmid: 25125670
references.citation: Bioorg Med Chem Lett. 2011 Jun 1;21(11):3216-21
references.pmid: 21549597
references.citation: Chem Commun (Camb). 2015;51(2):302-5
references.pmid: 25407638
references.citation: Subcell Biochem. 2014;75:349-59
references.pmid: 24146387
references.citation: Bioorg Med Chem Lett. 2013 Dec 15;23(24):6759-63
references.pmid: 24189056
references.citation: Osteoporos Int. 2013 Mar;24(3):763-70
references.pmid: 23306823
references.citation: Cell. 1994 Sep 23;78(6):919-25
references.pmid: 7923361
references.citation: Nitric Oxide. 2008 Sep;19(2):146-51
references.pmid: 18474261
references.citation: Eur J Med Chem. 2014 Sep 12;84:240-6
references.pmid: 25019479
references.citation: Expert Opin Ther Pat. 2013;23(6):705-16
references.pmid: 23627893
references.citation: Arch Oral Biol. 2015 Apr;60(4):557-65
references.pmid: 25601046
references.citation: Nitric Oxide. 2008 Sep;19(2):192-8
references.pmid: 18485922
references.citation: Cancer Lett. 2014 Oct 10;353(1):1-7
references.pmid: 25079686
references.citation: Bioorg Med Chem. 2010 May 15;18(10):3559-63
references.pmid: 20430631
references.citation: Bioorg Med Chem. 2013 Nov 15;21(22):7210-5
references.pmid: 24090602
references.citation: Vision Res. 1996 Sep;36(18):2979-94
references.pmid: 8917798
references.citation: Expert Opin Ther Pat. 2012 Jan;22(1):79-88
references.pmid: 22191414
references.citation: Mini Rev Med Chem. 2005 Feb;5(2):217-29
references.pmid: 15720291
references.citation: J Enzyme Inhib Med Chem. 2012 Dec;27(6):759-72
references.pmid: 22468747
references.citation: Bioorg Med Chem Lett. 2009 Dec 1;19(23):6565-70
references.pmid: 19854054
references.citation: Bioorg Med Chem. 2014 Aug 1;22(15):3982-8
references.pmid: 25027802
references.citation: J Enzyme Inhib Med Chem. 2012 Feb;27(1):138-47
references.pmid: 21815773
references.citation: Drug Discov Today. 2004 Aug 1;9(15):641-51
references.pmid: 15279847
references.citation: Br J Pharmacol. 2007 Jun;151(3):305-21
references.pmid: 17401442
references.citation: Curr Med Chem. 2012;19(3):386-405
references.pmid: 22335514
references.citation: Chem Rev. 2012 Aug 8;112(8):4421-68
references.pmid: 22607219
references.citation: Bioorg Med Chem. 2014 Mar 15;22(6):1821-31
references.pmid: 24560739
references.citation: Planta Med. 2015 Apr;81(6):533-40
references.pmid: 25590364